Active Ingredients of Reduning Injection Maintain High Potency against SARS-CoV-2 Variants*

XIAO Zhen1,2, XU Huan3, QU Ze-yang1,2, MA Xin-yuan4, HUANG Bo-xuan2,5, SUN Meng-si3, WANG Bu-qing6, and WANG Guan-yu1,2,7,8

ABSTRACT  Objective: To investigate the anti-coronavirus potential and the corresponding mechanisms of the two ingredients of Reduning Injection: quercetin and luteolin. Methods: A pseudovirus system was designed to test the efficacy of quercetin and luteolin to inhibit SARS-CoV-2 infection and the corresponding cellular toxicity. Luteolin was tested for its activities against the pseudoviruses of SARS-CoV-2 and its variants. Virtual screening was performed to predict the binding sites by Autodock Vina 1.1.230 and PyMol. To validate docking results, surface plasmon resonance (SPR) was used to measure the binding affinity of the compounds with various proteins of the coronaviruses. Quercetin and luteolin were further tested for their inhibitory effects on other coronaviruses by indirect immunofluorescence assay on rhabdomyosarcoma cells infected with HCoV-OC43. Results: The inhibition of SARS-CoV-2 pseudovirus by luteolin and quercetin were strongly dose-dependent, with concentration for 50% of maximal effect (EC_{50}) of 8.817 and 52.98 μmol/L, respectively. Their cytotoxicity to BHK21-hACE2 were 177.6 and 405.1 μmol/L, respectively. In addition, luteolin significantly blocked the entry of 4 pseudoviruses of SARS-CoV-2 variants, with EC_{50} lower than 7 μmol/L. Virtual screening and SPR confirmed that luteolin binds to the S-proteins and quercetin binds to the active center of the 3CLpro, PLpro, and helicase proteins. Quercetin and luteolin showed over 99% inhibition against HCoV-OC43. Conclusions: The mechanisms were revealed of quercetin and luteolin inhibiting the infection of SARS-CoV-2 and its variants. Reduning Injection is a promising drug for COVID-19. KEYWORDS Reduning injection, Chinese medicine, luteolin, quercetin, SARS-CoV-2

The corona virus disease 2019 (COVID-19) pandemic has become a global health emergency. The spike protein (S-protein) of SARS-CoV-2, consisting of S1 and S2 subunits, is critical to receptor recognition and virus-cell fusion. SARS-CoV-2 binds to host cell receptors via the receptor-binding domain (RBD) of S1, which induces the formation of 6-helical bundle (6-HB) between the two heptad repeats (HRs) in S2, namely HR1 and HR2, and the consequential conformational change of S2, which facilitates the virus-membrane fusion. In December 2020, several effective SARS-CoV-2 vaccines were authorized. However, the emergence of new SARS-CoV-2 strains attenuates the efficacy of vaccines and neutralization antibodies.1,2

Reduning Injection (热毒宁注射液, RDN), approved by the Chinese Food and Drug Administration in 2005, is a Chinese medicine (CM) prepared from Lonicerae Japonicae Flos, Artemisiae Annuae Herba, and Gardeniae Fructus. CM has...
been very helpful to control the COVID-19 epidemic. We recently found CM ingredients effective to emerging coronaviruses, such as thymoquinone, resveratrol, and polydatin. We suspected that RDN would be effective to COVID-19 because it evidently has antibacterial, antiviral, antipyretic, and anti-inflammatory effects, and it has been used to treat a variety of infectious diseases. Ma, et al tested RDN in COVID-19 patients and characterized its antiviral activity. They found that RDN markedly inhibited SARS-CoV-2 proliferation and viral plaque formation in vitro and reduced inflammatory cytokine production in the infected cells. Gao, et al reported the molecular mechanisms and network pharmacology of RDN inhibiting SARS-CoV-2. Fifty effective components, corresponding to 208 targets, were identified. Network topology analysis revealed that quercetin, kaempferol, luteolin, isohamnetin, and chryseriol are the compounds that have the highest degree value. Based on these in vitro tests and clinical evaluations, RDN was incorporated into the Diagnosis and Treatment Programs of 2019 New Coronavirus Pneumonia, which was formulated by the National Health Commission of China. It has also been highly recommended by the National Health Council and National Administration of Chinese Medicine (Trial 7th edition, 2020) for the diagnosis and treatment of pneumonia caused by SARS-CoV-2. Quercetin, an active ingredient of RDN, can prevent the entry of many viruses, including rhinovirus and poliovirus, and reduce their cytopathic effects. As a strong antioxidant and scavenger flavonoid without any adverse effects, it is effective on the prophylaxis and treatment of coronavirus infections. Quercetin can block SARS-CoV entry into Vero E6 cells with a half maximal effective concentration (EC₅₀) of 83.4 μmol/L and a half maximal cytotoxic concentration (CC₅₀) of 3.32 mmol/L. Luteolin, another active ingredient of RDN, has in vitro antiviral activities against a wide range of viruses. The mechanism of luteolin inhibiting the fusion of SARS-CoV with the host cell membrane was revealed. FAC/MS identified the high affinity of luteolin with the S2 subunit of the S-protein of SARS-CoV, whose HR regions are crucial for the virus-membrane fusion. The interaction of HR1 and HR2 forms a 6-HB to bring viral and cellular membranes in close proximity. Hence, the S2 subunit of the S-protein of SARS-CoV-2 (SARS-CoV-2-S), as well as host proteases such as cathepsin L and TMPRSS2, are attractive therapeutic targets. Bioinformatic analyses, Shawan, et al found that luteolin belongs to the most effective flavonoids among a total of 43 flavonoids. Luteolin bound the target proteins with the lowest binding free energy and inhibition constant. The ΔG₀ (Kᵢ) values are –8.2 kcal/mol (927.87 nmol/L), –7.1 kcal/mol (5980.37 nmol/L), and –10.1 kcal/mol (37.13 nmol/L) for the main protease (3CLpro), Papain-like protease (PLpro), and angiotensin-converting enzyme 2 (ACE2), respectively. Here a pseudovirus system was used to test the efficacy of quercetin and luteolin to inhibit SARS-CoV-2 infection. We tested their effects on SARS-CoV-2 pseudovirus and found that luteolin significantly inhibited viral infection. We thus speculated that luteolin potently inhibits SARS-CoV-2 by blocking the formation of 6-HB. Surface plasmon resonance (SPR) confirmed that luteolin binds with S2, which was consistent with previous results on SARS-CoV. We also tested luteolin against genetic variants of SARS-CoV-2, including alpha variant B.1.1.7, beta variant B.1.351, delta variant B.1.617, and omicron.

**METHOD**

**Materials**

Quercetin was purchased from MedChemExpress (Monmouth Junction, NJ, USA); luteolin was purchased from Targetmol (Shanghai, China). The Trans1-T1 strain, F-ψ 80(lacZ) ΔM15ΔlacX74hsdR+ rKm) ΔrecA 1398endAltonA (TransGen Biotech, Beijing, China) was used to clone and propagate plasmid DNA. Miniprep and Maxiprep kits (Axygen, USA) were used to harvest and purify plasmid DNA. 3CLpro and PLpro of SARS-CoV-2, SARS-CoV, and MERS-CoV were purchased from Novoprotein (Beijing, China) or expressed and purified by Genescript (Nanjing, China). The S2-proteins of SARS-CoV-2 and SARS-CoV, the S1+S2 ECD of MERS-CoV, HC0-OC43, NL63-CoV, and HKU1-CoV were purchased from Sinobiologic (Beijing, China). CM5 chip and phosphate surfactant P20 (PBS-P) buffer were purchased from GE healthcare (Uppsala, Sweden). The 12-mer fluorogenic peptide substrates Dabcyl-KKNSTLQSLRKEDans and Dabcyl-KRLGGSKPIKGE-Edans and Dabcyl-KRLKGAPIKGE-Edans, respectively for 3CLpro and PLpro inhibition assays, were synthesized by Genescript (Nanjing, China). BHK21-hACE2 cells were maintained in high glucose Dulbecco’s modified
Eagle medium (DMEM) with 10% fetal bovine serum (FBS) and 1% antibiotic/antimycotic.

VSV-dG-fLuc are recombinant vesicular stomatitis virus variants with G protein deletion, expressing firefly luciferase (fLuc). The VSV-dG-fLuc pseudoviruses were generated through plasmid-based reverse genetics system. The pBluescript-N (pBS-N), pBS-P, pBS-L and pBS-G are helper vectors for the first round virus rescue. The plasmid pVSV-dG-fLuc, as well as the helper vectors, were purchased from Kerafast (Boston, MA, USA). The genes encoding the coronaviruses were synthesized by Genescript.

Expression and Purification of Recombinant Nsp13 of SARS-CoV-2 and SARS-CoV

The pET28a vectors for Nsp13 of SARS-CoV-2 and SARS-CoV were provided by Profs. AN Wenlin and HUANG Jian-dong, respectively. The proteins were expressed in BL21(DE3) cells and purified using a Ni-affinity column and a FPLC Superdex 200 Increase column.\(^{(21,22)}\)

Viruses and Cell Lines

HCoV-OC43 was purchased from American Type Culture Collection (ATCC VR-1558) and propagated using rhabdomyosarcoma (RD) cells (ATCC CCL-136). HCoV-OC43 stock virus was obtained from RD cells in DMEM supplemented with 2% FBS at 72 h post-infection (hpi). Viral titer (PFU/mL) was determined by plaque assay. BHK21-hACE2 was kindly provided by Prof. YAN Huan from Wuhan University.

VSV-Based Pseudovirus Production

VSV pseudotypes coated with the wide type (wt) and variant of SARS-CoV-2-S were generated based on a previously described protocol with slight modification.\(^{(23)}\) HEK-293T or Vero-E6 cells were transfected with a plasmid overexpressing codon-optimized (i.e., the deletion of C-terminal 18 amino acids) SARS-CoV-2-S, which was able to significantly improve the pseudotypes packaging efficiency.\(^{(24,25)}\) After 24 h, the cells were transduced with VSV-dG-fluc at multiplicity of infection (MOI) = 10 IU. After 1 h incubation at 37 °C, the cells were washed by culture medium once and then replenished with fresh culture medium with anti-VSV rat serum to eliminate the infectivity of the residual input viruses. The SARS-CoV-2-S pseudotyped VSV viruses were harvested 24 h after transduction by clarification at 12,000 r/min for 2 min and then stored at −80 °C. The virus titer was determined by a plaque assay on BHK21-hACE2 cells with serial-diluted inocula.

SARS-CoV-2 Pseudovirus Inhibition Assay

BHK21-hACE2 cells were seeded in 96-well plates. After 24 h, the cells were inoculated with SARS-CoV-2 pseudotyped VSV (MOI = 0.1 IU) expressing luciferase diluted using DMEM with 10% FBS in the presence of indicated chemicals of varying concentrations (100, 33, 11, 3.7, 1.23, 0.41, and 0.137 μmol/L for the tested compounds). About 16–20 h after infection, the cells infected with the pseudoviruses expressing firefly luciferase were lysed by 1 × passive lysis buffer (Promega, Madison, USA) at room temperature for 15 min, and the luciferase activity was evaluated by One-Glo luciferase assay kit (Promega) through a GloMax® 20/20 Luminometer. The cytotoxicity of the tested chemicals was evaluated by bright field images before fluorescence imaging or cell lysis. The median effective concentration (EC\(_{50}\)) was determined by nonlinear regression analysis.

Virtual Screening

The PDB files of SARS-CoV-2 3CLpro (PDB: 6lu7), SARS-CoV 3CLpro (pdb: 2duc), MERS-CoV 3CLpro (PDB: 4rsp), SARS-CoV-2 helicase (PDB: 6zsl), and SARS-CoV-2-S (PDB: 6vxx)\(^{(26,27)}\) were downloaded from http://www.rcsb.org/\(^{(28,29)}\) All heterogeneous atoms and the bound ligands were removed. The chain A of 6lu7, 2duc, 4rsp, 6zsl, and 6vxx were selected for the subsequent molecular docking by Autodock Vina 1.1.2.\(^{(30)}\) The protein–ligand interactions were visualized by using PyMol. For 3CLpro, helicase, and S-protein, the interactive residues were defined to be those whose distances to the hit ligand were ≤1 Å, ≤2.5 Å, and ≤2.5 Å, respectively.\(^{(31)}\) The ligands with binding energy lower than −6 kcal/mol were selected as candidates for the subsequent experimental verification.

SPR Based Analysis

To measure the binding affinities of quercetin/luteolin with the 3CLpro and PLpro of SARS-CoV-2, SARS-CoV, MERS-CoV, the helicase of SARS-CoV-2 and SARS-CoV, and the S-proteins of SARS-CoV-2, SARS-CoV, MERS-CoV, HCoV-OC43, NL63-CoV and HKU1-CoV, a SPR based Biacore T200 biosensor (Biacore AB, Uppsala, Sweden) with CMS 5 was used as the sensor chip. At 25 °C, the target proteins...
were diluted to a final concentration of 20 μg/mL in 10 mmol/L sodium acetate buffer (pH 4.5) and then immobilized to CM5 by the standard primary amine coupling method. The CM5 surface was first activated by injecting a 1:1 mixture containing 200 mmol/L 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride and 50 mmol/L N-hydroxysuccinimide for a target level of 10,000 RU at a flow rate of 20 μL/min. The target proteins were then injected to CM5 surface, which was then blocked by injecting 1 mol/L ethanolamine at pH 8.5 for 7 min. During the immobilization, HBS-EP running buffer (10 mmol/L HEPES, 150 mmol/L NaCl, 3.4 mmol/L EDTA, and 0.005% v/v surfactant P20, pH 7.4) was used. All the screening assays were performed over the unmodified dextran surface and the protein surface. For sample dilution, the pH and the concentration of both dimethyl sulfoxide (DMSO) and buffer substances in samples and running buffer were carefully matched. Each sample assay consisted of a 180-s buffer injection and a 300-s dissociation phase and the blank injection was used to check the carryover effects. The signal was adjusted for nonspecific binding of the samples to dextran matrix by subtracting the signal in the reference channel from the signal in the active channel. The experimental data were fitted and analyzed using the BIA evaluation software (Cytiva, Sweden) by steady state analysis.

**RESULTS**

**EC_{50} and CC_{50} of Quercetin and Luteolin for SARS-CoV-2 Pseudovirus**

By adding different compound concentrations from 0.137 to 100 μmol/L, it was found that the inhibition of SARS-CoV-2 pseudovirus entry into the BHK21-hACE2 cells was strongly dose-dependent. For luteolin, EC_{50} = 8.817 μmol/L, CC_{50} = 177.6 μmol/L, selectivity index = 20.14. For quercetin, EC_{50} = 52.98 μmol/L, CC_{50} = 405.1 μmol/L, selectivity index = 7.65 (Figure 1). These data suggested that quercetin and luteolin are both effective against SARS-CoV-2 infection, with luteolin much stronger considering its small EC_{50}. Therefore, luteolin was chosen in the following as the compound to inhibit the pseudoviruses of SARS-CoV-2 variants.

**EC_{50} of Luteolin Inhibiting Pseudoviruses of SARS-CoV-2 Variants**

Luteolin significantly blocked the entry of the pseudoviruses of SARS-CoV-2 alpha variant B.1.1.7, beta variant B.1.351, delta variant B.1.617, and the recent variant omicron, with EC_{50} being 6.44, 5.605, 4.635, and 3.489 μmol/L, respectively (Figure 2).

**Quercetin and Luteolin Binding Site Prediction**

Chain A of SARS-CoV-2-3CLpro (PDB: 6lu7), SARS-CoV-3CLpro (2duc), MERS-CoV-3CLpro (4rsp), and SARS-CoV-2-helicase (6zsl) were extracted to dock with quercetin, which was found to bind to the sites formed by MET49, LEU141, HIS163, MET165, GLU166, ASP187 GLN189 of 6lu7 (Figure 3A), THR25, CYS44, GLU47, ASP48, MET49, MET165 of 2duc (Figure 3B), HIS41, PHE143, HIS166, MET168, GLU169, LYS191 of 4rsp (Figure 3C), and GLY-287, GLY289, LYS290, GLN406, ARG569 of 6zsl (Figure 3D), respectively. Then, chain A of SARS-CoV-2-S (6vxx) was docked with luteolin, which forms hydrogen bonds with S2 residues SER749, THR797 and ALA1075; HIS1077 may also participate
in the interaction (Figure 3E). These results suggest that luteolin inhibits the infection of SARS-CoV-2 by disturbing the formation of the 6-HB fusion core.

SPR-Based Binder Identification

To validate our docking results, we used SPR to measure the affinity of luteolin and quercetin binding with various proteins of the coronaviruses (Appendix 1). The proteins were immobilized on CM5 chips. We let the compounds flow across the CM5 surface and found that the binding were strongly dose-dependent, including luteolin binding to the S-proteins and quercetin binding to the active center of the 3CLpro, PLpro, and helicase proteins (Table 1).

Anti-HCoV-OC43 Activity of Quercetin and Luteolin

The result of IFA on RD cells showed that quercetin and luteolin significantly suppressed HCoV-OC43 replication. Over 99% inhibition was achieved at the 11.11 μ mol/L concentration (Figure 4).

DISCUSSION

Since the outbreak of COVID-19, scientists have been assiduously finding effective methods to treat coronavirus infection. For example, Wei, et al. (29) adopted an in silico drug repurposing strategy; by
molecular docking, they searched Food and Drug Administration-approved drugs from DrugBank and natural compounds from Traditional Chinese Medicine Systems Pharmacology (TCMSP) for the compounds that can potentially interrupt the interaction between human ACE2 and SARS-CoV-2-S; they found more than 20 molecules binding to SARS-CoV-2-S with high affinity. CM has a long history to treat viral infection and proves to be effective in therapeutics via the direct inhibition of viral proliferation and the enhanced immune function.

RDN is a CM recommended for treating COVID-19. It has multiple pharmacological activities, including, antiviral,\(^5\) antipyretic,\(^6\) and anti-inflammatory,\(^7\) antibacteria,\(^8\) lung injury treatment,\(^9\) etc. Among the ingredients of RDN, luetolin and quercetin were identified as key active ingredients to inhibit many viruses. Owing to pleiotropy and nontoxicity of quercetin, a clinical trial (NCT04377789) was started to evaluate quercetin against COVID-19. The synergism of quercetin with vitamins C/D may provide alternative or additional therapeutic and preventive options due to their overlapping antiviral and immunomodulatory properties.

We designed SARS-CoV-2 pseudoparticles containing SARS-CoV-2-S assembled onto luciferase reporter gene-carrying VSV core particles based on the genome sequence of SARS-CoV-2 released on 01/12/2020.\(^32\) These pseudotyped particles faithfully reflect key aspects of the entry of native SARS-CoV-2 into host cells via binding to the ACE2 receptors; they can thus be used to test entry inhibitors of SARS-CoV-2.\(^33\) Luteolin inhibited SARS-CoV infection of Vero E6 cells with an EC\(_{50}\) of 10.6 μmol/L and CC\(_{50}\) of 155 μmol/L, while quercetin antagonized the entry of HIV-luc/SARS pseudo-types with EC\(_{50}\) of 83.4 μmol/L.\(^16\) We found that luteolin and quercetin inhibit SARS-CoV-2 pseudovirus with EC\(_{50}\) of

| Compound          | Proteins           | KD (μmol/L) | Rmax (RU) | Chi\(^2\) (RU\(^2\)) | Chi   |
|-------------------|--------------------|-------------|-----------|-----------------------|-------|
| Luteolin SARS-CoV-2 S2 | 25.57              | 6.50        | 0.0125    | 0.112                 |       |
| SARS S1+S2 ECD    | 2.31               | 6.20        | 0.0508    | 0.225                 |       |
| MERS S1+S2 ECD    | 38.62              | 2.16        | 0.0066    | 0.081                 |       |
| OC43 S1+S2 ECD    | 7.88               | 6.72        | 0.3150    | 0.561                 |       |
| NL63 S1+S2 ECD    | 83.44              | 33.83       | 0.0753    | 0.274                 |       |
| HKU1 S1+S2 ECD    | 38.18              | 26.46       | 0.0135    | 0.116                 |       |
| Quercetin SARS-CoV-2 3CLpro | 0.92             | 4.22        | 0.0650    | 0.255                 |       |
| SARS-CoV-2 PLpro   | 7.72               | 44.15       | 6.2300    | 2.500                 |       |
| SARS 3CLpro       | 5.97               | 26.92       | 5.7800    | 2.404                 |       |
| SARS PLpro        | 10.67              | 35.18       | 0.0096    | 0.098                 |       |
| MERS 3CLpro       | 33.64              | 40.65       | 0.7030    | 0.839                 |       |
| MERS PLpro        | 7.71               | 24.60       | 4.0000    | 2.000                 |       |
| SARS-CoV-2 helicase| 9.43               | 24.16       | 3.2300    | 1.800                 |       |
| SARS-CoV helicase | 7.37               | 36.93       | 4.8800    | 2.210                 |       |

Figure 4. Luteolin and Quercetin on RD Cells Infected with HCoV-OC43 by Immunofluorescence Assay
SARS-CoV-2 variants have been circulating around the world. These variants were found to spread more easily than the original virus and to evade vaccine protections. The majority of the entry inhibitors were designed to target the RBD-ACE2 interaction. However, targeting this domain showed limited cross-reactivity because RBD is poorly conserved across human coronaviruses. The alpha, gamma, beta, delta, and omicron variants of SARS-CoV-2 have emerged, with some mutations identified in the RBD. In contrast, S2 is highly conserved and can potentially serve as a broad-spectrum target. To test luteolin, we designed the pseudoviruses of SARS-CoV-2 variants that contain the mutant S-protein assembled onto luciferase reporter gene-carrying VSV core particles. We have confirmed the broad-spectrum property of luteolin in targeting S2 of pseudoviruses of SARS-CoV-2 variants: alpha variant B.1.1.17, beta variant B.1.351, delta variant B.1.617, and omicron, with EC$_{50}$ values of 6.44, 5.605, 4.635, and 3.489 µmol/L, respectively.

Our in vitro studies showed that luteolin bound to the S-protein of coronaviruses such as SARS-CoV-2, SARS-CoV, MERS-CoV, HCoV-OC43, NL63-CoV, and HKU1-CoV, with the respective dissociation constants (KD) being 25.57, 2.308, 38.62, 7.878, 83.44, and 38.18 µmol/L, respectively. The responses were strongly dose-dependent. Quercetin, although not a strong inhibitor of the S-protein, has high affinities with PLpro, 3CLpro, and NTPase/helicase, which are key proteins facilitating the coronavirus replication. It bound to 3CLpro of SARS-CoV-2, SARS-CoV, and MERS-CoV, with KD being 0.920, 5.972, and 33.64 µmol/L, respectively; it bound to PLpro of SARS-CoV-2, SARS-CoV, and MERS-CoV, with KD being 7.715, 10.67, and 7.712 µmol/L, respectively; it bound to the helicase of SARS-CoV-2 and SARS-CoV, with KD being 9.43 and 7.37 µmol/L, respectively. The above results are consistent with the molecular docking studies of both ourselves and others.

The broad spectrum of luteolin and quercetin were also confirmed by targeting HCoV-OC43, a relative of SARS-CoV-2. For luteolin in particular, over 99% inhibition was achieved at 11.11 µmol/L concentration. Debiaggi, et al. found that 60 µg/mL quercetin reduced the infectivity of bovine coronaviruses NCDCV by 50%. Hence, quercetin and luteolin may be effective to several members of the Coronaviridae family.

In conclusion, RDN is potentially effective against SARS-CoV-2, and we have tentatively revealed the underlying mechanisms upon which in-depth studies can be based.

Conflict of Interest
The authors declare no conflicts of interest.

Author Contributions
Xu H, Wang GY acquired funding and supervised the project. Xiao Z, Xu H, Sun MS performed the experiments. Xu H, Wang GY and Xiao Z were responsible for writing and revising the article. Qu ZY did the virtual screening. Ma XY, Huang BX and Wang BQ analyzed the data. Xiao Z, Xu H and Qu ZY contributed to this work equally. All the authors read and approved the final version of manuscript.

Acknowledgement
We thank Bioimaging Core and Biochemical Analysis Platform of Shenzhen Bay Laboratory for providing imaging and SPR support. We also would like to acknowledge Bioimaging Core engineer HUANG Shi-xian for assistance with fluorescence microscope.

Electronic Supplementary Material: Supplementary material (Appendix 1) is available in the online version of this article at https://doi.org/10.1007/s11655-022-3686-5.

REFERENCES
1. Andrea DT. Outbreak of a novel coronavirus. Nat Rev Microbiol 2020;18:123.
2. Carlos WG, Dela C, Charles S, Cao B, Pasnick S, Jamil S. Novel Wuhan (2019-nCoV) Coronavirus. Am J Respir Crit Care Med 2020;2020:7-8.
3. Xu H, Liu B, Xiao Z, Zhou ML, Ge L, Jia F, et al. Computational and experimental studies reveal that thymoquinone blocks the entry of coronaviruses into in vitro cells. Infect Dis Ther 2021;10:483-494.
4. Xu H, Li J, Song SD, Xiao Z, Chen XQ, Huang BX, et al. Effective inhibition of coronavirus replication by Polygonum cuspidatum. Front Biosci-Landmark 2021;26:789-798.
5. Zhang GL, Zhao J, He LY, Yan SY, Zhuo ZQ, Zheng HJ, et al. Reducing injection for fever, rash, and ulcers in children with mild hand, foot, and mouth disease: a randomized controlled clinical study. J Tradit Chin Med 2013;33:733-742.
6. Chen J, Chang XJ, Chen CM, Lyu YZ, Zhou J, Wang ZZ, et al. Study on analgesic and antipyretics effect of Re-Du-Ning injection. World Sci Techn Modem Tradit Chin Med (Chin) 2014;16:1912-1915.
7. Tang LP, Xiao W, Li YF, Li HB, Wang ZZ, Yao XS, et al. Anti-inflammatory effects of Reduning Injection on lipo polysaccharide-induced acute lung injury of rats. Chin J Integr Med 2014;20:591-599.
8. Gao W, Wang S, Cui Z, Cao J, Tian H. Reduning injection for induced acute lung injury of rats. Chin J Integr Med 2014;20:591-599.
community-acquired pneumonia: meta-analysis. China J Chin Mater Med (Chin) 2011;36:3539-3543.
9. Chang XJ, Zhang S, Chen J, Chen CM, Zhou J. Effect of Reduning Injection on acute lung injury of rats. Chin J Exp Tradit Med Form (Chin) 2014;20:591-599.
10. Ma Q, Xie Y, Wang Z, Lei B, Chen R, Liu B, et al. Efficacy and safety of Reduning injection as a treatment for COVID-19 and its inhibitory effect against SARS-CoV-2. J Ethnopharmacol 2021;279:114367.
11. Gao Y, Liu M, Yang K, Shi S, Liu Y, Sun W, et al. Preliminary study on the effective components and mechanism of Reduning Injection in the treatment of corona virus disease 2019. China Med Guide (Chin) 2020;22:145-152.
12. Ganesan S, Faris AN, Comstock AT, Wang Q, Nanua S, Hershenson MB, et al. Quercetin inhibits rhinovirus replication in vitro and in vivo. Antiviral Res 2012;94:256-271.
13. Nezanov N, Kondratova A, Chumakov KM, Nezanovna L, Kondratov R, Banerjee AK, et al. Quercetinase pirin makes poliovirus replication resistant to flavonoid quercetin. DNA Cell Biol 2008;27:191-198.
14. Zhang M, Swarts SG, Yin L, Liu C, Tian Y, Cao Y, et al. Antioxidant properties of quercetin. Adv Exp Med Biol 2011;701:283-289.
15. Chen L, Jian L, Cheng L, Hong L, Xu W, Chen G, et al. Binding interaction of quercetin-3-beta-galactoside and its synthetic derivatives with SARS-CoV 3CL(pro): structure-activity relationship studies reveal salient pharmacophore features. Bioorg Med Chem 2006;14:8295-8306.
16. Yi L, Li Z, Yuan K, Xu X, Chen J, Wang G, et al. Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells. J Virol 2004;78:11334-11339.
17. Zakaryan H, Arabyan E, Oo A, Zandi K. Flavonoids: promising natural compounds against viral infections. Arch Virol 2017;162:2539-2551.
18. Wong SS, Yuen KY. The management of coronavirus infections with particular reference to SARS. J Antimicrob Chemother 2001;62:437-441.
19. Luo E, Zhang D, Luo H, Liu B, Zhao K, Zhao YH, et al. Treatment efficacy analysis of traditional Chinese medicine for novel coronavirus pneumonia (COVID-19): an empirical study from Wuhan, Hubei Province. China Chin Med 2020;15:1-13.
20. Shawan MMAK, Halder SK, Hasan MA, Luteolin and abyssinone II as potential inhibitors of SARS-CoV-2: an in silico molecular modeling approach in battling the COVID-19 outbreak. Bull Natl Res Cent 2021;45:27.
21. Tanner JA, Watt RM, Chai YB, Lu LY, Lin MC, Peiris JSM, et al. The severe acute respiratory syndrome (SARS) coronavirus NTPase/helicase belongs to a distinct class of 5’ to 3’ viral helicases. J Biol Chem 2003;278:39578-39582.
22. White MA, Lin W, Chen X. Discovery of COVID-19 inhibitors targeting the SARS-CoV Nsp13 helicase. J Phys Chem Lett 2020;11:9144-9151.
23. Whitt MA. Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. J Virol Methods 2010;169:365-374.
24. Fukushima S, Mizutani T, Saijo M, Matsuyama S, Miyajima N, Taguchi F, et al. Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike protein. J Gen Virol 2005;86:2269-2274.
25. Schwegmann-Weßels C, Glende J, Ren XF, Qu XX, Deng HK, Enjuanes L, et al. Comparison of vesicular stomatitis virus pseudotyped with the S proteins from a porcine and a human coronavirus. J Gen Virol 2009;90:1724-1729.
26. Walls AC, Park YJ, Tortorici MA, Wall A, Guire ATM, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020;181:281-292.e286.
27. Newman JA, Yosaatmadja Y, Douangamath A, Arrowsmith CH, von Delft F, Edwards A, et al. Crystal structure of the SARS-CoV-2 helicase at 1.94 Angstrom resolution. Protein Data Bank. Available at: https://doi.org/10.2210/pdb6ZSL/pdb.
28. Berman H, Westbrook J, Feng ZK, Weissig H. The Protein Data Bank. Nucleic Acids Res 2003;31:235-242.
29. Wei T, Wang H, Wu XQ, Lu Y, Guan SH, Dong FQ, et al. In silico screening of potential spike glycoprotein inhibitors of SARS-CoV-2 with drug repurposing strategy. Chin J Integr Med 2020;26:663-669.
30. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2015;36:455-461.
31. The PyMOL Molecular Graphics System, Version 1.8. Schrödinger, LLC.
32. Wu F, Zhao S, Yu B, Chen YM, Zhang YZ. A new coronavirus associated with human respiratory disease in China. Nature 2020;579:265-269.
33. Xiong HL, Wu YT, Cao JL, Yang R, Liu YX, Ma J, et al. Robust neutralization assay based on SARS-CoV-2 S-protein-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressing BHK21 cells. Emerg Microbes Infect 2021;9:2105-2113.
34. Zhou B, Thao TTN, Hoffmann D, Taddeo A, Ebert N, Labroussaa F, et al. SARS-CoV-2 spike D614G change enhances replication and transmission. Nature 2021;592:122-127.
35. Volz E, Hill V, Mccrone JT, Price A, Connor TR. Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity. Cell 2020;184:64-75.
36. Debiaggi M, Tateo F, Pagani L, Luni M, Romero E. Effects of propolis flavonoids on virus infectivity and replication. Microbiologia 1990;13:207-213.
37. Hu K, Guan WJ, Bi Y, Zhang W, Zhong NS. Efficacy and safety of Reduning injection as a treatment for COVID-19 and its inhibitory effect against SARS-CoV-2. J Ethnopharmacol 2020;212:205-212.
38. Chatterjee S, Maiti S, Bannerjee A, Kanwar M. In-silico study of hesperedin, epigallocatechin (EGCG), kaempferol and quercetin. Res Sq Preprint 2021; https://doi.org/10.21203/rs.3.rs-525091/v1.
(Accepted August 5, 2022; First Online November 14, 2022) Edited by YUAN Lin